Login Register Cart 0
Generic placeholder image

Combinatorial Chemistry & High Throughput Screening

Editor-in-Chief

ISSN (Print): 1386-2073
ISSN (Online): 1875-5402

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Screening GLP-1 Receptor Ligands from Natural Products in Herbs through High-Content Technique

Author(s): Kunhao Qin, Shengting Zhang, Jie Wang, Dongbo Liu, Yingying Xiang, Xiuling Ji and Yunlin Wei*

Volume 22, Issue 7, 2019

Page: [445 - 454] Pages: 10

DOI: 10.2174/1386207322666190919143735

Price: $65

Abstract

Aim and Objective: Screening of active components from a natural product, especially from a crude extract, is a great challenge. To avoid potential activity interference of the N-terminus modification in the most common constructs based on GCPRs labeled with GFP technology, a Cterminus tGFP-labeled hGLP-1 receptor containing recombinant cell line hGLP-1R-tGFP was constructed and tried to be used in the screening of natural products from Chinese herb.

Materials and Methods: The GLP1 receptor gene was amplified and the inserts pCMV6-AC-tGFP and tGFP were fused at the C-terminus of GLP1 receptor to construct a recombinant plasmid. The recombinant was transfected into U2OS cell and selected with antibiotics and flow cytometry. The constructed cell line was named as hGLP-1R-tGFP cell line. The expression levels of GLP-1R-tGFP protein were confirmed by western-blot. The fluorescence imaging of re-distribution from diffusing to aggregate spots inside the cells was quantitated and analyzed by High Content Screening (HCS) assay. Meanwhile, the specificity, stability and C-terminus function of hGLP-1R-tGFP cell line were characterized. In order to allow the recombinant cell line of hGLP-1R-tGFP to be suitable in highcontent system of Arrayscan-infinity-700 in screening mode, several conditions have also been optimized. In the end, a total of 100 crude extract samples provided by the Yunnan Institute of Materia Medica have been screened with this method.

Results: Upon the activation of GLP-1 receptors by Exendin 4, fluorescent patches appeared on the cell membrane and subsequently internalized to form fluorescent aggregates inside the cells under fluorescent microscopy examination. The agonistic activity, sensitivity and specificity of the formation of fluorescent aggregate spot in hGLP-1R-tGFP cells have been confirmed by the activation of GLP-1R using the GLP-1analogues. The agonistic effects of GLP-1 analogues are blocked by a GLP-1R antagonist, Exendin9-39. The downstream of GLP-1 pathway, the activation of adenylate cyclase and the raising of cellular cAMP levels, remained intact in these tGFP modified C-terminus GLP-1 receptor cells. Meanwhile, a total of 100 crude extract samples from Chinese herbs have been screened by this method to find new active ingredients.

Conclusion: Combined with High Content Screening image and data automatic acquisition processing, a new screening assay based on a recombinant U2OS cell line which GFP labeled at the C terminus of GLP1 receptor has been developed. GLP-1R agonist activity in extracts of Astragalus propinquus and Panax notoginseng from Chinese herbs has been determined by this method.

Keywords: High-content screening, tGFP, GLP-1R, GLP-1 analogue, screening, Chinese herbs.

« Previous Next »
[1]
Dong, Y.H.; Zhang, L.; Gao, W.G.; Wang, N.; Wei, J.; Hammar, N.; Cabrera, C.; Qiao, Q. Patient characteristics related to metabolic disorders and chronic complications in type 2 diabetes mellitus patients hospitalized at the Qingdao Endocrine and Diabetes Hospital from 2006 to 2012 in China. Diabetes Metab. Rev., 2015, 31, 18-19.
[2]
Dong, Y.; Gao, W.; Zhang, L.; Wei, J.; Hammar, N.; Cabrera, C.S.; Wu, X.; Qiao, Q. Patient characteristics related to metabolic disorders and chronic complications in type 2 diabetes mellitus patients hospitalized at the Qingdao Endocrine and Diabetes Hospital from 2006 to 2012 in China. Diab. Vasc. Dis. Res., 2017, 14(1), 24-32.
[http://dx.doi.org/10.1177/1479164116675489] [PMID: 27941053]
[3]
Dauriz, M.; Trombetta, M.; Santi, L.; Boselli, M.; Brangani, C.; Pichiri, I.; Travia, D.; Cacciatori, V.; Negri, C.; Stoico, V.; Bonadonna, R.C.; Bonora, E. Relationship of chronic vascular complications with beta cell dysfunction and insulin resistance in newly-diagnosed type 2 diabetes. The VNDS Study. Diabetologia, 2017, 60, S502-S502.
[4]
Mauvais-Jarvis, F.; Virkamaki, A.; Michael, M.D.; Winnay, J.N.; Zisman, A.; Kulkarni, R.N.; Kahn, C.R. A model to explore the interaction between muscle insulin resistance and beta-cell dysfunction in the development of type 2 diabetes. Diabetes, 2000, 49(12), 2126-2134.
[http://dx.doi.org/10.2337/diabetes.49.12.2126] [PMID: 11118016]
[5]
Ahren, B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat. Rev. Drug Discov., 2010, 12-28.
[6]
Willard, F.S.; Sloop, K.W. Physiology and emerging biochemistry of the glucagon-like peptide-1 receptor. Exp. Diabetes Res., 2012, 2012470851
[http://dx.doi.org/10.1155/2012/470851] [PMID: 22666230]
[7]
Vilsbøll, T.; Holst, J.J. Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia, 2004, 47(3), 357-366.
[http://dx.doi.org/10.1007/s00125-004-1342-6] [PMID: 14968296]
[8]
Nauck, M.A.; Heimesaat, M.M.; Behle, K.; Holst, J.J.; Nauck, M.S.; Ritzel, R.; Hüfner, M.; Schmiegel, W.H. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J. Clin. Endocrinol. Metab., 2002, 87(3), 1239-1246.
[http://dx.doi.org/10.1210/jcem.87.3.8355] [PMID: 11889194]
[9]
Ban, K.; Kim, K.H.; Cho, C.K.; Sauvé, M.; Diamandis, E.P.; Backx, P.H.; Drucker, D.J.; Husain, M. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology, 2010, 151(4), 1520-1531.
[http://dx.doi.org/10.1210/en.2009-1197] [PMID: 20172966]
[10]
Ahren, B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat. Rev. Drug Discov., 2009, 8(8), 626-626.
[http://dx.doi.org/10.1038/nrd2971]
[11]
Charbonnel, B.; Thiriet, C.; Guerci, B. Contribution of a composite criterion of a new revaluation GLP1 analogue, liraglutide. Diabetes Metab., 2010, 36, A76-A76.
[http://dx.doi.org/10.1016/S1262-3636(10)70307-4]
[12]
O’Brien, P.J.; Irwin, W.; Diaz, D.; Howard-Cofield, E.; Krejsa, C.M.; Slaughter, M.R.; Gao, B.; Kaludercic, N.; Angeline, A.; Bernardi, P.; Brain, P.; Hougham, C. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol., 2006, 80(9), 580-604.
[http://dx.doi.org/10.1007/s00204-006-0091-3] [PMID: 16598496]
[13]
Boudjelal, M.; Ruiz-Avendano, A.M.; Colmenarejo, G.; Senar-Sancho, S.A.; Barnes, A.; Harrison, S.A. High throughput screening assay to identify modulators of IL-17 expression. Comb. Chem. High Throughput Screen., 2017, 20(9), 804-819.
[http://dx.doi.org/10.2174/1386207320666170602091308] [PMID: 28571538]
[14]
Skoglund, G.; Hussain, M.A.; Holz, G.G. Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element. Diabetes, 2000, 49(7), 1156-1164.
[http://dx.doi.org/10.2337/diabetes.49.7.1156] [PMID: 10909973]
[15]
De Vries, L.; Finana, F.; Cathala, C.; Ronsin, B.; Cussac, D.; Gatti-McArthur, S. An internalization assay for Dopamine D2(short) Receptors using Bioluminescence Resonance Energy Transfer (BRET) technology. FASEB J., 2017, 31, Abstract Number: lb567..
[16]
Sheng, Z.; Zhang, J.F.; Li, C.Y.; Chen, L.G. Fluorescent switching technology based on fluorescence resonance energy transfer for detecting dimethoate pesticides in environmental water. Anal Methods-Uk, 2016, 8(48), 8506-8513.
[http://dx.doi.org/10.1039/C6AY02803A]
[17]
Li, S.; Long, C.; Liu, F.; Lee, S.; Guo, Q.; Li, R.; Liu, Y. Herbs for medicinal baths among the traditional Yao communities of China. J. Ethnopharmacol., 2006, 108(1), 59-67.
[http://dx.doi.org/10.1016/j.jep.2006.04.014] [PMID: 16735101]
[18]
Ghosh, R.N.; Chen, Y.T.; DeBiasio, R.; DeBiasio, R.L.; Conway, B.R.; Minor, L.K.; Demarest, K.T. Cell-based, high-content screen for receptor internalization, recycling and intracellular trafficking. Biotechniques, 2000, 29(1), 170-175.
[http://dx.doi.org/10.2144/00291pf01] [PMID: 10907092]
[19]
Bellomo, F.; Medina, D.L.; De Leo, E.; Panarella, A.; Emma, F. High-content drug screening for rare diseases. J. Inherit. Metab. Dis., 2017, 40(4), 601-607.
[http://dx.doi.org/10.1007/s10545-017-0055-1] [PMID: 28593466]
[20]
Donato, M.T.; Gómez-Lechón, M.J.; Tolosa, L. Using high-content screening technology for studying drug-induced hepatotoxicity in preclinical studies. Expert Opin. Drug Discov., 2017, 12(2), 201-211.
[http://dx.doi.org/10.1080/17460441.2017.1271784] [PMID: 27936962]
[21]
Li, M.R.; Ji, X.L.; Min, Z.; Chang, K.J.; Liu, D.B.; Wei, Y.L. In Establishment of a GFP Fluorescence Labeled GLP-1 Receptor Cell Line AASRI International Conference on Industrial Electronics and Applications (IEA 2015), In: Advances in Engineering Research; Atlantis Press:, 2015; pp. 2352-5401.
[http://dx.doi.org/10.2991/iea-15.2015.170]]
[22]
Thompson, A.; Kanamarlapudi, V. The regions within the N-terminus critical for human glucagon like peptide-1 receptor (hGLP-1R) cell Surface expression. Sci. Rep., 2014, 4, 7410.
[23]
Thompson, A.; Kanamarlapudi, V. Distinct regions in the C-Terminus required for GLP-1R cell surface expression, activity and internalisation. Mol. Cell. Endocrinol., 2015, 413(C), 66-77.
[http://dx.doi.org/10.1016/j.mce.2015.06.012] [PMID: 26116235]
[24]
Bavec, A.; Licar, A. Functional characterization of N-terminally GFP-tagged GLP-1 receptor. J. Biomed. Biotechnol., 2009, 2009498149
[http://dx.doi.org/10.1155/2009/498149] [PMID: 19859570]
[25]
Schirra, J.; Sturm, K.; Leicht, P.; Arnold, R.; Göke, B.; Katschinski, M. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J. Clin. Invest., 1998, 101(7), 1421-1430.
[http://dx.doi.org/10.1172/JCI1349] [PMID: 9525985]
[26]
Wassermann, A.M.; Lounkine, E.; Urban, L.; Whitebread, S.; Chen, S.; Hughes, K.; Guo, H.; Kutlina, E.; Fekete, A.; Klumpp, M.; Glick, M. A screening pattern recognition method finds new and divergent targets for drugs and natural products. ACS Chem. Biol., 2014, 9(7), 1622-1631.
[http://dx.doi.org/10.1021/cb5001839] [PMID: 24802392]
[27]
Koole, C.; Wootten, D.; Simms, J.; Miller, L.J.; Christopoulos, A.; Sexton, P.M. Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation. J. Biol. Chem., 2012, 287(6), 3642-3658.
[http://dx.doi.org/10.1074/jbc.M111.309328] [PMID: 22147710]
[28]
Darsalia, V.; Nathanson, D.; Nyström, T.; Klein, T.; Sjöholm, Å.; Patrone, C. GLP-1R activation for the treatment of stroke: updating and future perspectives. Rev. Endocr. Metab. Disord., 2014, 15(3), 233-242.
[http://dx.doi.org/10.1007/s11154-014-9285-9] [PMID: 24777909]
[29]
Zhao, X.; Liu, G.; Shen, H.; Gao, B.; Li, X.; Fu, J.; Zhou, J.; Ji, Q. Liraglutide inhibits autophagy and apoptosis induced by high glucose through GLP-1R in renal tubular epithelial cells. Int. J. Mol. Med., 2015, 35(3), 684-692.
[http://dx.doi.org/10.3892/ijmm.2014.2052] [PMID: 25573030]
[30]
Liu, J.; Hu, Y.; Xu, Y.; Jia, Y.; Miao, L.; Wang, G. Comparison of exenatide and metformin monotherapy in overweight/obese patients with newly diagnosed type 2 diabetes. Int. J. Endocrinol., 2017, 20179401606
[http://dx.doi.org/10.1155/2017/9401606] [PMID: 29358950]
[31]
Vandenburgh, H. High-content drug screening with engineered musculoskeletal tissues. Tissue Eng. Part B Rev., 2010, 16(1), 55-64.
[http://dx.doi.org/10.1089/ten.teb.2009.0445] [PMID: 19728786]
[32]
Or, P.M.; Lam, F.F.; Kwan, Y.W.; Cho, C.H.; Lau, C.P.; Yu, H.; Lin, G.; Lau, C.B.; Fung, K.P.; Leung, P.C.; Yeung, J.H. Effects of Radix Astragali and Radix Rehmanniae, the components of an anti-diabetic foot ulcer herbal formula, on metabolism of model CYP1A2, CYP2C9, CYP2D6, CYP2E1 and CYP3A4 probe substrates in pooled human liver microsomes and specific CYP isoforms. Phytomedicine, 2012, 19(6), 535-544.
[http://dx.doi.org/10.1016/j.phymed.2011.12.005] [PMID: 22261394]
[33]
Wu, T.; Sun, J.; Kagota, S.; Maruyama, K.; Wakuda, H.; Shinozuka, K. Panax notoginseng saponins ameliorate impaired arterial vasodilation in SHRSP.Z-Lepr(fa)/lzmDmcr rats with metabolic syndrome. Clin. Exp. Pharmacol. Physiol., 2016, 43(4), 459-467.
[http://dx.doi.org/10.1111/1440-1681.12547] [PMID: 26784885]

Rights & Permissions Print Cite
Article Metrics
47
4
© 2024 Bentham Science Publishers | Privacy Policy